Advances in CAR-T Cell Therapy: Personalized Immunotherapy and the Future of Precision Cancer Treatment

Authors:
Publisher website
Google Scholar
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as one of the most significant advances in contemporary oncology, representing a transformative approach within the field of personalized cancer immunotherapy. By genetically engineering T lymphocytes to recognize and eliminate malignant cells through specific antigen-targeting mechanisms, CAR-T therapy has demonstrated remarkable clinical efficacy in several hematological malignancies, including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. This review analyzes the biological foundations, clinical applications, therapeutic outcomes, safety considerations, and future perspectives associated with CAR-T technology. The available evidence indicates that CAR-T therapy has achieved unprecedented response rates in patients with relapsed or refractory disease, significantly improving treatment possibilities for populations with historically poor prognoses. However, important challenges remain regarding treatment-related toxicities, manufacturing complexity, economic sustainability, accessibility, and limited effectiveness in solid tumors. Recent advances in genetic engineering, synthetic biology, biomarker discovery, and precision medicine are driving the development of next-generation CAR-T platforms designed to enhance efficacy, safety, and applicability across a broader spectrum of cancers. Furthermore, growing interest in Latin America, particularly in Mexico, Colombia, and Ecuador, reflects increasing efforts to expand access to advanced cellular therapies through academic collaboration, translational research, and healthcare innovation. The findings suggest that CAR-T therapy will continue to play a central role in the evolution of precision oncology and may serve as a model for future individualized therapeutic strategies in cancer management.